Reaction
Anal Cancer reporting signals
As of the last recalculation, Anal Cancer appears in 963 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is RITONAVIR 100 MG (PRR 32.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ritonavir 100 Mg | 22 | 32.6 | 32.6 |
| Nevirapine | 12 | 29.1 | 29.1 |
| Lopinavir And Ritonavir | 15 | 24.3 | 24.3 |
| Ritonavir | 31 | 23.7 | 23.7 |
| Raltegravir | 17 | 22.6 | 22.7 |
| Efavirenz | 11 | 21.6 | 21.6 |
| Darunavir | 14 | 20.3 | 20.3 |
| Atazanavir | 10 | 15.2 | 15.2 |
| Ranitidine Hydrochloride | 33 | 13.6 | 13.6 |
| Abacavir Sulfate | 6 | 13.4 | 13.4 |
| Dolutegravir Sodium | 4 | 9.6 | 9.6 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 19 | 9.2 | 9.2 |
| Ranitidine | 72 | 8.4 | 8.4 |
| Tenofovir Disoproxil Fumarate | 12 | 7.9 | 7.9 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 6 | 7.2 | 7.2 |
| Sofosbuvir | 6 | 6.6 | 6.6 |
| Diroximel Fumarate | 3 | 5.5 | 5.5 |